News & Updates

Diuretic, too, lowers BP in advanced kidney disease

11 Nov 2021 by

The thiazide diuretic chlorthalidone significantly reduces systolic blood pressure (SBP) by an average of 10 mm Hg in patients with refractory hypertension and advanced chronic kidney disease (CKD), reveals the CLICK* study presented at ASN 2021 — thus debunking the conventional belief that thiazide diuretics do not work in patients with advanced CKD.

Diuretic, too, lowers BP in advanced kidney disease

11 Nov 2021

Discrepancies, interventions greater in patients discharged with psychotropic drugs

11 Nov 2021

Thirty-day readmissions are similar between patients who had at least one psychotropic medication upon discharge and those who had none, reports a study. However, the former has a higher number of discrepancies that require significantly more discharge interventions during a pharmacist-driven discharge medication reconciliation (DMR).

Discrepancies, interventions greater in patients discharged with psychotropic drugs

11 Nov 2021

COVID-19 mRNA vaccines effective in real-world study of HCPs

10 Nov 2021 by

A test-negative, case-control study demonstrated the real-world effectiveness of the BNT162b2 vaccine (Pfizer–BioNTech) and mRNA-1273 vaccine (Moderna) among healthcare personnel in the US.

COVID-19 mRNA vaccines effective in real-world study of HCPs

10 Nov 2021

Possible allergic reaction should not delay COVID-19 vaccination

10 Nov 2021 by

People who had an allergic response to the first dose of COVID-19 vaccination or who believe they will have an allergy to vaccination should not let their worries delay getting vaccinated — as most of them can still be fully vaccinated safely, suggest studies presented at ACAAI 2021.

Possible allergic reaction should not delay COVID-19 vaccination

10 Nov 2021

Concurrent painkiller use dims outcomes in aspirin-treated patients

10 Nov 2021 by

Comedication with the analgesic dipyrone appears to contribute to excess mortality among patients receiving aspirin for secondary cardiovascular disease (CVD) prevention, partly driven by an increase in ischaemic events, a study from Germany has found.

Concurrent painkiller use dims outcomes in aspirin-treated patients

10 Nov 2021

Belimumab after rituximab reduces risk for severe flare in SLE

10 Nov 2021

Treatment with belimumab following rituximab significantly lowers serum IgG anti-dsDNA antibody levels and the risk for severe flare in patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, reveals a study.

Belimumab after rituximab reduces risk for severe flare in SLE

10 Nov 2021

A3 adenosine receptor agonist safe, effective for treating NAFLD

10 Nov 2021

Namodenoson, an A3 adenosine receptor (A3AR) agonist, shows clinical activity against nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH), according to data from a phase II study.

A3 adenosine receptor agonist safe, effective for treating NAFLD

10 Nov 2021

4F-PCC effective in reversal of FXa inhibitor-related acute major bleeding

09 Nov 2021

Use of a 4-factor prothrombin complex concentrate (4F-PCC) for oral factor Xa (FXa) inhibitor-related acute major bleeding appears to work for most patients, results of a recent study have shown.

4F-PCC effective in reversal of FXa inhibitor-related acute major bleeding

09 Nov 2021

Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics

09 Nov 2021

Type 2 diabetes (T2D) patients exposed to hydrochlorothiazide for more than 2 years appear to be at higher risk of cutaneous squamous cell carcinoma (cSCC), as reported in a recent study.

Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics

09 Nov 2021

Trastuzumab deruxtecan can be safely used with ritonavir, itraconazole for HER2+ diseases

09 Nov 2021

Concomitant administration of the human epidermal growth factor receptor 2 (HER2)–targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) with the OATP1B/CYP3A inhibitor ritonavir or the strong CYP3A inhibitor itraconazole appears to be safe and does not produce a clinically meaningful change in the pharmacokinetics of T-DXd or DXd, according to a phase I study.

Trastuzumab deruxtecan can be safely used with ritonavir, itraconazole for HER2+ diseases

09 Nov 2021

News & Updates

Filter by Specialty:

Specialty:

Diuretic, too, lowers BP in advanced kidney disease

Diuretic, too, lowers BP in advanced kidney disease

Discrepancies, interventions greater in patients discharged with psychotropic drugs

Discrepancies, interventions greater in patients discharged with psychotropic drugs

COVID-19 mRNA vaccines effective in real-world study of HCPs

COVID-19 mRNA vaccines effective in real-world study of HCPs

Possible allergic reaction should not delay COVID-19 vaccination

Possible allergic reaction should not delay COVID-19 vaccination

Concurrent painkiller use dims outcomes in aspirin-treated patients

Concurrent painkiller use dims outcomes in aspirin-treated patients

Belimumab after rituximab reduces risk for severe flare in SLE

Belimumab after rituximab reduces risk for severe flare in SLE

A3 adenosine receptor agonist safe, effective for treating NAFLD

A3 adenosine receptor agonist safe, effective for treating NAFLD

4F-PCC effective in reversal of FXa inhibitor-related acute major bleeding

4F-PCC effective in reversal of FXa inhibitor-related acute major bleeding

Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics

Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics

Trastuzumab deruxtecan can be safely used with ritonavir, itraconazole for HER2+ diseases

Trastuzumab deruxtecan can be safely used with ritonavir, itraconazole for HER2+ diseases